SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central […]
Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that it will be hosting a booth at the upcoming Life Sciences Day on the Hill on February 16, 2022, at the Utah State Capital Building. It is expected that the conference, […]
New Nelson Labs Mark offers transparency and confidence in product testing […]
Fluidx Medical Reports Initial Research on First-of-its-Kind Embolic Agent with Intermediate Radiopacity […]
Biomerics inaugurated its second plant in Costa Rica. […]
Fluidx Medical’s Novel Embolic Device Demonstrates Repeated Success in Treating Complex Tumors […]
Foldax Appoints Scott Huennekens to Board of Directors […]
PolarityTE, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the evaluation of SkinTE for the treatment of chronic cutaneous ulcers. […]
Co-Diagnostics, Inc. announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its SARAGENE™ Human Papillomavirus High-Risk (HPV-HR) Real-Time PCR test as an in vitro diagnostic (“IVD”) […]
New Peripheral Vascular Microcatheters Save Procedure Time and Advance Treatment Capabilities […]
Positive Study Results Published for KidneyIntelXTM in Monitoring Patient Response to New Drug Therapy […]
Premier Neurology Facility in Colorado Joins the CenExel Centers of Excellence […]